Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CartiHeal's Agili-C Implant Wins Breakthrough Status - Orthopedic Design & Technology
OEM News

CartiHeal’s Agili-C Implant Wins Breakthrough Status

Clinical study is currently evaluating Agili-C implant's superiority over the current surgical standard of care.

CartiHeal, developer of Agili-C, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced FDA has granted Breakthrough Device Designation for the Agili-C implant.
 
FDA’s Breakthrough Device Program is reserved for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.  This program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA.
 
CartiHeal is currently conducting a pivotal IDE clinical study which is designed to evaluate the Agili-C implant superiority over the current surgical standard of care—microfracture and debridement. In total 251 Subjects were enrolled in 26 sites in the US, Europe and Israel. The study includes Subjects with both mild to moderate osteoarthritis and focal defects, without arthritic changes. Final study results are expected next year.
 
“We are extremely pleased that FDA granted the Agili-C implant Breakthrough Device Designation,” said Nir Altschuler, CartiHeal’s founder and CEO. “We look forward to working closely with FDA to expedite Agili-C’s review process, once the final IDE study results will be available, in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters